United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of March, 2018

 

Commission File Number: 001-35892

  

 

GW PHARMACEUTICALS PLC

(Translation of registrant’s name into English)

 

 

Sovereign House

Vision Park

Histon

Cambridge CB24 9BZ

United Kingdom

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x Form 40-F  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes  ¨ No  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes  ¨ No  ¨

 

 

 

 

 

 

Notification of Interests Of Directors, Officers And Connected Persons

 

GW Pharmaceuticals plc (the “Company”) hereby provides notification that on March 8, 2018, Adam George, Company Secretary and UK Managing Director exercised options under the Company’s Long Term Incentive Plan and sold 17,200 American Depositary Shares (“ADSs”) at a price of $116.67 per ADS in accordance with his Rule 10b5-1 plan established February 14, 2018. Further details are set forth in the table below.

 

1. Details of the person discharging managerial responsibilities / person closely associated
a. Name Adam George
2. Reason for the notification
a. Position/status UK Managing Director
b. 

Initial notification /Amendment

Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name GW Pharmaceuticals PLC
b. LEI  
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.

Description of the Financial instrument, type of instrument

Identification code

American Depositary Shares

ISIN: 36197T1034

b. Nature of the transaction Exercise of Long Term Incentive Plan options and sale of resulting American Depositary Shares in accordance with 10b5.1 plan dated 14 February 2018
c. Price(s) and volume(s)

Price(s)  

$116.67

Volume(s)

17,200  

 

ADS’s sold

d.

Aggregated information

· Aggregated volume

· Price

 

n/a

e.  Date of the transaction March 8, 2018
f. Place of the transaction Nasdaq, New York

 

For further information, please contact:

  

GW Pharmaceuticals PLC   +44 (0)1980 557 000
Adam George, Company Secretary  

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GW Pharmaceuticals plc
     
  By: /s/ Adam George
  Name: Adam George
  Title: Company Secretary
     
Date: March 13, 2018